IP Library › Granted Patent US 12,268,750
Granted Patent B2
US 12,268,750 · App. 18/821,737 · Granted Apr 8, 2025

Immunoconjugates and methods

Inventors: Xiaojun Han (San Diego, CA); Suvi Tuula Marjukka Orr (San Diego, CA); Kevin Duane Bunker (Escondido, CA); Peter Qinhua Huang (San Diego, CA); Kimberlee Fischer (San Diego, CA)
Assignee: Immunome, Inc.
A61K47/6803A61K31/4745A61K47/55A61K47/6851C07K16/18A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,750
App. No.
18/821,737
Granted
Apr 8, 2025
Kind
B2
Abstract

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer. Ab-[S-L 1 -L 2 -L 3 -L 4 -L 5 -L 6 -L 7 -D] n    (I)

Claims (8)

1. An antibody or antigen-binding fragment thereof that specifically binds human receptor tyrosine kinase like orphan receptor 1 (ROR1), comprising:

a) a variable heavy chain region (VH) comprising: (i) a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (ii) VHCDR2 comprising the amino acid sequence of SEQ ID NO: 2; and (iii) a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

b) a variable light chain region (VL) comprising: (i) a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 8; ii) a VLCDR2 comprising the amino acid sequence AAS; and iii) a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 10.

2. An antibody or antigen-binding fragment thereof that specifically binds human receptor tyrosine kinase like orphan receptor 1 (ROR1), comprising:

a) a variable heavy chain region (VH) comprising: (i) a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 15; (ii) VHCDR2 comprising the amino acid sequence of SEQ ID NO: 16; and (iii) a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 17; and

b) a variable light chain region (VL) comprising: (i) a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 22; ii) a VLCDR2 comprising the amino acid sequence DAY; and iii) a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 24.

3. An antibody or antigen-binding fragment thereof that specifically binds human receptor tyrosine kinase like orphan receptor 1 (ROR1), comprising:

a) a variable heavy chain region (VH) comprising: (i) a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 29; (ii) VHCDR2 comprising the amino acid sequence of SEQ ID NO: 30; and (iii) a VHCDR3 comprising the amino acid sequence of SEQ ID NO: 31; and a variable light chain region (VL) comprising: (i) a VLCDR1 comprising the amino acid sequence of SEQ ID NO: 36; ii) a VLCDR2 comprising the amino acid sequence DAS; and iii) a VLCDR3 comprising the amino acid sequence of SEQ ID NO: 38.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2024
From: ZENO MANAGEMENT, INC.
To: RECURIUM IP HOLDINGS, LLC
Reel/Frame 069127/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2024
From: RECURIUM IP HOLDINGS, LLC
To: ZENO MANAGEMENT, INC.
Reel/Frame 069128/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: ZENO MANAGEMENT, INC.
To: IMMUNOME, INC.
Reel/Frame 069081/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2024
From: HAN, XIAOJUN; ORR, SUVI TUULA MARJUKKA; BUNKER, KEVIN DUANE; HUANG, PETER QINHUA; FISCHER, KIMBERLEE
To: ZENO MANAGEMENT, INC.
Reel/Frame 068455/0900 →
Continuity (6)
Continuation 18479317 · Oct 2, 2023
Continuation 17936346 · Sep 28, 2022
Continuation In Part 17812869 · Jul 15, 2022
Provisional Application 63267471 · Feb 2, 2022
Provisional Application 63203347 · Jul 19, 2021
Related Publication 20240424124A1 · Dec 26, 2024
References Cited (202)
US 5856448A · Coughlin · 1999 [cited by applicant]
US 5990084A · Richter et al. · 1999 [cited by applicant]
US 6197541B1 · Coughlin · 2001 [cited by applicant]
US 6291671B1 · Inoue et al. · 2001 [cited by applicant]
US 6436912B1 · Inoue et al. · 2002 [cited by applicant]
US 6590061B1 · Rypacek et al. · 2003 [cited by applicant]
US 6656458B1 · Philippe et al. · 2003 [cited by applicant]
US 6835807B1 · Susaki et al. · 2004 [cited by applicant]
US 6838450B2 · Inoue et al. · 2005 [cited by applicant]
US 7439231B2 · Olson et al. · 2008 [cited by applicant]
US 7601796B2 · Breitenkamp et al. · 2009 [cited by applicant]
US 8067544B2 · Landes et al. · 2011 [cited by applicant]
US 8217005B2 · Jenkins et al. · 2012 [cited by applicant]
US 8222215B2 · Olson et al. · 2012 [cited by applicant]
US 8268936B2 · Breitenkamp et al. · 2012 [cited by applicant]
US 8598312B2 · Olson et al. · 2013 [cited by applicant]
US 8747904B2 · Mirosevich et al. · 2014 [cited by applicant]
US 8921418B2 · Jenkins et al. · 2014 [cited by applicant]
US 9040032B2 · Jenkins et al. · 2015 [cited by applicant]
US 9095557B2 · Stohr · 2015 [cited by applicant]
US 9150647B2 · Mellstedt et al. · 2015 [cited by applicant]
US 9217040B2 · Kipps et al. · 2015 [cited by applicant]
US 9220785B2 · Adami et al. · 2015 [cited by applicant]
US 9228023B2 · Rohlff et al. · 2016 [cited by applicant]
US 9248109B2 · Yu et al. · 2016 [cited by applicant]
US 9376381B2 · Yu · 2016 [cited by applicant]
US 9446011B2 · Stöhr · 2016 [cited by applicant]
US 9585963B2 · Jenkins et al. · 2017 [cited by applicant]
US 9597410B2 · Bachovchin et al. · 2017 [cited by applicant]
US 9758591B2 · Kipps et al. · 2017 [cited by applicant]
US 9808537B2 · Masuda et al. · 2017 [cited by applicant]
US 9821067B2 · Adami et al. · 2017 [cited by applicant]
US 9872924B2 · Naito et al. · 2018 [cited by applicant]
US 9956297B2 · Bachovchin et al. · 2018 [cited by applicant]
US 10155821B2 · Naito et al. · 2018 [cited by applicant]
US 10195288B2 · Masuda et al. · 2019 [cited by applicant]
US 10287317B2 · Muehlemann et al. · 2019 [cited by applicant]
US 10335496B2 · Lannutti et al. · 2019 [cited by applicant]
US 10383878B2 · Hettmann et al. · 2019 [cited by applicant]
US 10398783B2 · McDonald et al. · 2019 [cited by applicant]
US 10414826B2 · Doronina et al. · 2019 [cited by applicant]
US 10517955B2 · Bachovchin et al. · 2019 [cited by applicant]
US 10729782B2 · Naito et al. · 2020 [cited by applicant]
US 10808039B2 · Doronina et al. · 2020 [cited by applicant]
US 10869934B2 · McDonald et al. · 2020 [cited by applicant]
US 10906974B2 · Iida et al. · 2021 [cited by applicant]
US 10968275B2 · Balakrishnan et al. · 2021 [cited by applicant]
US 10973924B2 · Masuda et al. · 2021 [cited by applicant]
US 11155615B2 · Wong et al. · 2021 [cited by applicant]
US 11242388B2 · Rader et al. · 2022 [cited by applicant]
US 11806405B1 · Han et al. · 2023 [cited by applicant]
US 20010043935A1 · Philippe et al. · 2001 [cited by applicant]
US 20020164360A9 · Philippe et al. · 2002 [cited by applicant]
US 20100273714A1 · Stoehr · 2010 [cited by applicant]
US 20110105381A2 · Jenkins et al. · 2011 [cited by applicant]
US 20130210854A1 · Jenkins et al. · 2013 [cited by applicant]
US 20150297748A1 · Masuda et al. · 2015 [cited by applicant]
US 20160333112A1 · Naito et al. · 2016 [cited by applicant]
US 20170035906A1 · Naito et al. · 2017 [cited by applicant]
US 20190077880A1 · Naito et al. · 2019 [cited by applicant]
US 20190151328A1 · Hettmann et al. · 2019 [cited by applicant]
US 20190153092A1 · Waldmeier et al. · 2019 [cited by applicant]
US 20190209702A1 · Han · 2019 [cited by applicant]
US 20190224330A1 · Wang et al. · 2019 [cited by applicant]
US 20190225686A1 · Iida et al. · 2019 [cited by applicant]
US 20190330368A1 · Jikoh et al. · 2019 [cited by applicant]
US 20190343828A1 · Jeffrey et al. · 2019 [cited by applicant]
US 20190367631A1 · Gromada et al. · 2019 [cited by applicant]
US 20200040048A1 · Aivado et al. · 2020 [cited by applicant]
US 20200061031A1 · Yonesaka et al. · 2020 [cited by applicant]
US 20200282073A1 · Masuda et al. · 2020 [cited by applicant]
US 20200323994A1 · Bachovchin et al. · 2020 [cited by applicant]
US 20200384121A1 · Nishi et al. · 2020 [cited by applicant]
US 20200385422A1 · Yamaguchi et al. · 2020 [cited by applicant]
US 20200385486A1 · Naito et al. · 2020 [cited by applicant]
US 20210069342A1 · Park et al. · 2021 [cited by applicant]
US 20210077482A1 · Chari et al. · 2021 [cited by applicant]
US 20220008549A1 · Tsuda et al. · 2022 [cited by applicant]
US 20220323598A1 · Takahashi · 2022 [cited by applicant]
US 20230054458A1 · Yang et al. · 2023 [cited by applicant]
US 20230123041A1 · Han et al. · 2023 [cited by applicant]
US 20230330242A1 · Han et al. · 2023 [cited by applicant]
US 20240075153A1 · Han et al. · 2024 [cited by applicant]
AU 2021354823A1 · 2023 [cited by applicant]
AU 2022216696A1 · 2023 [cited by applicant]
CA 2145473A1 · 1995 [cited by applicant]
CA 3107417A1 · 2020 [cited by applicant]
CN 110721559A · 2020 [cited by applicant]
CN 111001012A · 2020 [cited by applicant]
CN 211328833U · 2020 [cited by applicant]
CN 111686259A · 2020 [cited by applicant]
CN 111689980A · 2020 [cited by applicant]
CN 112138171A · 2020 [cited by applicant]
CN 113816969A · 2021 [cited by applicant]
CN 2021101599566 · 2022 [cited by applicant]
CN 117715913A · 2024 [cited by applicant]
EP 0296597A2 · 1988 [cited by applicant]
EP 0673930A1 · 1995 [cited by applicant]
EP 0495432B1 · 1996 [cited by applicant]
EP 3632471A1 · 2020 [cited by applicant]
EP 3677589A1 · 2020 [cited by applicant]
EP 3831853A1 · 2021 [cited by applicant]
EP 3991754A1 · 2022 [cited by applicant]
EP 4183421A1 · 2023 [cited by applicant]
EP 4227309A1 · 2023 [cited by applicant]
JP H0687746A · 1994 [cited by applicant]
JP 2000044567A · 2000 [cited by applicant]
JP 2002060351A · 2002 [cited by applicant]
JP 2002146011A · 2002 [cited by applicant]
WO WO1996027370A1 · 1996 [cited by applicant]
WO WO1997040071A1 · 1997 [cited by applicant]
WO WO1999049837A1 · 1999 [cited by applicant]
WO WO1999064495A1 · 1999 [cited by applicant]
WO WO2001076603A1 · 2001 [cited by applicant]
WO WO2001098364A2 · 2001 [cited by applicant]
WO WO2003033671A2 · 2003 [cited by applicant]
WO WO2008000513A2 · 2008 [cited by applicant]
WO WO2008101202A1 · 2008 [cited by applicant]
WO WO2011133149A1 · 2011 [cited by applicant]
WO WO2011133150A1 · 2011 [cited by applicant]
WO WO2013173337A2 · 2013 [cited by applicant]
WO WO2014096551A1 · 2014 [cited by applicant]
WO WO2015057699A2 · 2015 [cited by applicant]
WO WO2015095755A1 · 2015 [cited by applicant]
WO WO2015123679A1 · 2015 [cited by applicant]
WO WO2015155998A1 · 2015 [cited by applicant]
WO WO2017165851A1 · 2017 [cited by applicant]
WO WO2018175994A1 · 2018 [cited by applicant]
WO WO2018237335A1 · 2018 [cited by applicant]
WO WO2019005636A2 · 2019 [cited by applicant]
WO WO2019034177A1 · 2019 [cited by applicant]
WO WO2019044947A1 · 2019 [cited by applicant]
WO WO2019136487A2 · 2019 [cited by applicant]
WO WO2019195665A1 · 2019 [cited by applicant]
WO WO2019219891A1 · 2019 [cited by applicant]
WO WO2019236954 · 2019 [cited by applicant]
WO WO2020022363A1 · 2020 [cited by applicant]
WO WO2020022475A1 · 2020 [cited by applicant]
WO WO2020031936A1 · 2020 [cited by applicant]
WO WO2020040245A1 · 2020 [cited by applicant]
WO WO2020050406A1 · 2020 [cited by applicant]
WO WO2020063673A1 · 2020 [cited by applicant]
WO WO2020063676A1 · 2020 [cited by applicant]
WO WO2020106780A1 · 2020 [cited by applicant]
WO WO2020122034A1 · 2020 [cited by applicant]
WO WO2020130125A1 · 2020 [cited by applicant]
WO WO2020146541A2 · 2020 [cited by applicant]
WO WO2020156513A1 · 2020 [cited by applicant]
WO WO2020160527A1 · 2020 [cited by applicant]
WO WO2020219287A1 · 2020 [cited by applicant]
WO WO2020237173A1 · 2020 [cited by applicant]
WO WO2020240467A1 · 2020 [cited by applicant]
WO WO2020244657A1 · 2020 [cited by applicant]
WO WO2020259258A1 · 2020 [cited by applicant]
WO WO2021052402A1 · 2021 [cited by applicant]
WO WO2021058027A1 · 2021 [cited by applicant]
WO WO2021115426A1 · 2021 [cited by applicant]
WO WO2021159029A1 · 2021 [cited by applicant]
WO WO2022001864A1 · 2022 [cited by applicant]
WO WO2022011075A1 · 2022 [cited by applicant]
WO WO2022033578A1 · 2022 [cited by applicant]
WO WO2022068878A1 · 2022 [cited by applicant]
WO WO2022078259A1 · 2022 [cited by applicant]
WO WO2022166762A1 · 2022 [cited by applicant]
WO WO2022174103A2 · 2022 [cited by applicant]
WO WO2022184082A1 · 2022 [cited by applicant]
WO WO2022217054A1 · 2022 [cited by applicant]
WO WO2023004266A1 · 2023 [cited by applicant]
WO WO2023078273A1 · 2023 [cited by applicant]
WO WO2023217064A1 · 2023 [cited by applicant]
WO WO2024020536A1 · 2024 [cited by applicant]
WO WO2024026323A1 · 2024 [cited by applicant]
WO WO2024067811A1 · 2024 [cited by applicant]
WO WO2024158996A2 · 2024 [cited by applicant]
Anonymous, Antibody-drug conjugates for cancer score with ROR1, Nat Biotechnol, 39(1): 10 (2021). [cited by applicant]
Casi, G., et al., Antibody-drug conjugates: basic concepts, examples and future perspectives, J Control Release, 161(2): 422-428 (2012). [cited by applicant]
Conilh, L., et al., Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform, Pharmaceuticals (Basel), 14(3): 247 (2021). [cited by applicant]
Ding, H.X., et al., Synthetic approaches to the 2011 new drugs, Bioorg Med Chem, 21(11):2795-2825 (2013). [cited by applicant]
Maderna, A., et al., Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications, J Med Chem, 57(24): 10527-10543 (2014). [cited by applicant]
Nejadmoghaddam, M-R., et al., Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna J Med Biotechnol, 11(1): 3-23 (2019). [cited by applicant]
Ogitani, Y., et al., Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity, Cancer Sci… [cited by applicant]
PCT/US2022/073780 International Search Report and Written Opinion mailed Nov. 4, 2022. [cited by applicant]
PCT/US2023/070971 International Search Report and Written Opinion mailed Oct. 30, 2023. [cited by applicant]
PCT/US2024/012923 International Search Report and Written Opinion mailed Aug. 22, 2024. [cited by applicant]
Renault, K., et al., Covalent Modification of Biomolecules through Maleimide-Based Labeling Strategies, Bioconjug Chem, 29(8): 2497-2513 (2018). [cited by applicant]
[cited by applicant]
Shiose, Y., et al., Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates, Bioconjug Chem, 20(1): 60-70 (2009). [cited by applicant]
Sugimori, M., et al., Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues, J Med Chem, 41(13): 2308-2318 (1998). [cited by applicant]
U.S. Appl. No. 17/936,346 Office Action mailed Jun. 30, 2023. [cited by applicant]
U.S. Appl. No. 17/936,346 Office Action mailed Mar. 15, 2023. [cited by applicant]
U.S. Appl. No. 18/479,317 Office Action mailed Apr. 18, 2024. [cited by applicant]
U.S. Appl. No. 18/479,317 Office Action mailed Dec. 14, 2023. [cited by applicant]
Xu, Z., et al., Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985), Eur J Med Chem, 183: 111682 (2019… [cited by applicant]
Yang, J., et al., Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies, PloS One, 6(6): e21018 (2011). [cited by applicant]
U.S. Appl. No. 17/812,869, filed Jul. 15, 2022, Pending. [cited by applicant]
U.S. Appl. No. 17/936,346, filed Sep. 28, 2022, U.S. Pat. No. 11,806,405, Nov. 7, 2023, Issued. [cited by applicant]
U.S. Appl. No. 18/479,317, filed Oct. 2, 2023, Allowed. [cited by applicant]
U.S. Appl. No. 18/821,707, filed Aug. 30, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/821,718, filed Aug. 30, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/821,728, filed Aug. 30, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/821,730, filed Aug. 30, 2024, Pending. [cited by applicant]
U.S. Appl. No. 18/821,749, filed Aug. 30, 2024, Pending. [cited by applicant]